P2X7 Receptor Antagonists
Gefapixant is a P2X7 Receptor Antagonists that has showed potential in the treatment of persistent cough that is refractory and undiagnosed. The goal of this trial was to compare the efficacy of gefapixant versus placebo after 12 weeks of treatment for refractory chronic cough or chronic cough that was not explained.
P2X3 antagonists are a new class of drugs being investigated to treat chronic cough that is refractory or unexplained. Gefapixant, the first P2X3 antagonist, is now in phase-III clinical trials and is awaiting FDA approval.
Read More @ https://cmiinfopiece.blogspot.com/2022/02/p2x7-receptor-antagonists-destroy.html
